Naional Jewish Health
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daley, Charles
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
MAC2v3, NCT03672630: Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Active, not recruiting
2/3
474
Canada, US
Azithromycin, Zithromax, Ethambutol, Myambutol, Rifampin, Rifadin
Kevin Winthrop, Patient-Centered Outcomes Research Institute, National Jewish Health, The University of Texas Health Science Center at Tyler, University Health Network, Toronto, New York University, Medical University of South Carolina, Mayo Clinic, Louisiana State University Health Sciences Center in New Orleans, University of California, San Diego, Stanford University, University of Kansas, Vancouver Clinic, University of California, San Francisco, University of Washington, Johns Hopkins University, University of Miami, Emory University, University of Iowa, University of North Carolina, Temple University, Loma Linda University, Columbia University, University of Wisconsin, Madison, Northwell Health, Kaiser Permanente Hawaii, James A. Haley Veterans Administration Hospital
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
10/25
10/25
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
02/24
02/24
NCT05730283: Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Recruiting
2
105
US
ORC-13661, Placebo
Kevin Winthrop, National Institute on Deafness and Other Communication Disorders (NIDCD), National Center for Advancing Translational Sciences (NCATS), Oricula Therapeutics, University of Washington, National Jewish Health, Mayo Clinic, The University of Texas Health Science Center at Tyler, Medical University of South Carolina
Ototoxicity, Drug-Induced
02/28
02/28
Lauzardo, Michael
No trials found
Ismail, Nahed
No trials found
Pride, David
No trials found
Gennaro, Maria
No trials found
Banaei, Niaz
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daley, Charles
ICoN-1, NCT06418711: Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Recruiting
3
234
US, RoW
Clofazimine Inhalation Suspension, MNKD-101, Placebo
Mannkind Corporation
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
08/26
12/28
MAC2v3, NCT03672630: Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Active, not recruiting
2/3
474
Canada, US
Azithromycin, Zithromax, Ethambutol, Myambutol, Rifampin, Rifadin
Kevin Winthrop, Patient-Centered Outcomes Research Institute, National Jewish Health, The University of Texas Health Science Center at Tyler, University Health Network, Toronto, New York University, Medical University of South Carolina, Mayo Clinic, Louisiana State University Health Sciences Center in New Orleans, University of California, San Diego, Stanford University, University of Kansas, Vancouver Clinic, University of California, San Francisco, University of Washington, Johns Hopkins University, University of Miami, Emory University, University of Iowa, University of North Carolina, Temple University, Loma Linda University, Columbia University, University of Wisconsin, Madison, Northwell Health, Kaiser Permanente Hawaii, James A. Haley Veterans Administration Hospital
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
10/25
10/25
NCT05495243: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed
2
40
US
ARINA-1, Placebo
Renovion, Inc.
Non-cystic Fibrosis Bronchiectasis
02/24
02/24
NCT05730283: Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Recruiting
2
105
US
ORC-13661, Placebo
Kevin Winthrop, National Institute on Deafness and Other Communication Disorders (NIDCD), National Center for Advancing Translational Sciences (NCATS), Oricula Therapeutics, University of Washington, National Jewish Health, Mayo Clinic, The University of Texas Health Science Center at Tyler, Medical University of South Carolina
Ototoxicity, Drug-Induced
02/28
02/28
Lauzardo, Michael
No trials found
Ismail, Nahed
No trials found
Pride, David
No trials found
Gennaro, Maria
No trials found
Banaei, Niaz
No trials found

Download Options